Skip Nav Destination
Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score
Issue Archive
Table of Contents
BLOOD COMMENTARIES
PERSPECTIVE
Antithrombotic therapy in abdominal aortic aneurysm: beneficial or detrimental?
CME
Clinical Trials & Observations
CLINICAL TRIALS AND OBSERVATIONS
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
Clinical Trials & Observations
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Clinical Trials & Observations
Brief Report
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
LETTER TO BLOOD
Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score
Clinical Trials & Observations
BLOOD WORK
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
Immunofluorescence staining for FOXO1 expression in murine Burkitt lymphoma (BL) cells (FOXO1 is shown in red; DAPI [4′,6-diamidino-2-phenylindole] labels the nuclei blue). Although phosphoinositide-3-kinase signaling is constantly active in BL cells, FOXO1 escapes nuclear exclusion by gaining genomic mutations. Importantly, proliferation and survival are promoted by nuclear FOXO1 in BL. See the article by Kabrani et al on page 2670.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
